

Crystal Rogers

From: Carole Baggerly [carole@grassrootshealth.org]
Sent: Wednesday, March 09, 2011 7:49 PM
To: Crystal Rogers
Cc: Heaney, Robert
Subject: Re: FW: Response to HCR 5--colon cancer + my comments

3/9/11

Crystal:

Re the colon cancer:

the Disease Incidence Chart has a Legend which states:

1. All percentages reference a common baseline of 25 ng/ml as shown on the chart
2. the x's in the bars indicate 'reasonable extrapolations' from the data but are beyond existing data.

On #1, the colon cancer item shows a 31% reduction *from 25 ng/ml* (not 50% from 12 ng/ml as in the paper). The reference point was changed to 25 ng/ml thus the % changed. There was a COMMON reference point of 25 ng/ml created so that all the papers could be compared to the same starting point.. all % are from 25 ng/ml.

#2, there are x's in the extension of the colon cancer line which represent what Dr. Garland considered a reasonable extrapolation of the the data to 42 ng/ml. At 42 ng/ml, there would be a 60% reduction in incidence compared with the baseline of 25 ng/ml.

I do not consider this erroneous or an omission but a different way of looking at the data.

Re the AADA letter, a few more of my own comments:

1. good to include the populations studied as noted in their pgh 1 on page 2
2. 'there are multiple studies that have suggested an inverse association between vitamin D intake and cancer.. etc....'

I would state that there are some very ambiguously analyzed data/methodologies that leave the conclusions open--certainly there is a need for more studies, but there are no well designed studies that I know of that show any negative associations with higher serum levels and cancer.

3. last page, agree that public AND physicians need to be educated about vitamin D... However, to encourage the individuals to consult with the physicians when the physicians are clearly also in need of education is a problem. (that is why we have developed the set of courses/videos that we have).

It is impressive that you have gotten their attention!!!! Congratulations. You're still on very solid ground.

Carole

Crystal Rogers wrote:

Hey Carole,

We just received a letter of opposition the day before the vitamin D hearing. Please let me know if you have any thoughts on this letter.

Is there anything written by Dr. Heaney about his Institute of Medicine's recommendations and what they did not take into consideration when creating their recommendations? The attached AAD letter says the IOM "released an exhaustive review of scientific literature," but was it Dr. Heaney's presentation, or your presentation that shows why the IOM was flawed in their review? I would be great to have this for the hearing tomorrow, which is 3:00--5:00 pm Alaska time.

Also, I am looking at the AAD's reference to the colorectal cancer; the chart prepared by you and Cedric Garland shows a 60% reduction in colorectal cancer with 42ng/ml, while the AAD's letter says is supposed to be a 50% reduction with 33ng/ml. I looked at the article abstract I found, and it appears the AAD's numbers match the article, but I honestly do not know if I am reading the article correctly.

For the article about Japanese school children, I don't understand the discrepancies between the AAD's letter and the Resolution's whereas statement.

Anything you have to add would be very helpful, especially if it will help clarify the IOM's recommendation due to what the vitamin D researchers are saying.

Thank you,

Crystal A. Rogers
Legislative Intern
Office of Representative Paul Seaton
Alaska State Legislature
(907) 465-6256

-----Original Message-----

From: Rep. Paul Seaton
Sent: Wednesday, March 09, 2011 4:44 PM
To: Crystal Rogers
Subject: FW: Response to HCR 5
Importance: High

-----Original Message-----

From: Kathryn Chandra [<mailto:KChandra@aad.org>]
Sent: Wednesday, March 09, 2011 2:18 PM
To: Rep. Wes Keller; Rep. Alan Dick; Rep. Bob Herron; Rep. Paul Seaton; Rep. Sharon Cissna; Rep. Bob Miller; Rep. Charisse Millett
Cc: jjordan@asmadocs.org
Subject: Response to HCR 5
Importance: High

Dear Representative Keller and Members of the House Health & Social Services Committee,

On behalf of the American Academy of Dermatology Association(AADA), attached is a letter which outlines several concerns with HCR 5. HCR 5 misrepresents several findings of the cited scientific literature, and as such endangers the health of Alaska's citizens by overemphasizing the role of vitamin D in disease prevention. The AADA would not want HCR 5 to be used as grounds to legitimize use of indoor tanning beds as a means for increasing vitamin D levels. We urge the committee to further review the scientific literature regarding vitamin D, and disease prevention before moving forward with a supplementation program aimed at specific, vulnerable segments of the population. Moreover, it is critical that the public be appropriately educated about vitamin D and be encouraged to consult their physician before taking any vitamin supplements.

Thank you for the opportunity to provide written comments to the Committee in advance of the hearing on HCR 5 on Thursday, March 10, 2011.

Sincerely,

Kathryn Guccione Chandra, MA
Assistant Director, State Policy
American Academy of Dermatology Association
1445 New York, Ave., NW, Suite 800
Washington, D.C. 20005-2134
Tel. 202-712-2615
Cell 202-739-1279
<mailto:kchandra@aad.org>kchandra@aad.org<mailto:kchandra@aad.org>

Disease Incidence Prevention by Serum 25(OH)D Level




Chart prepared by: Garland CF, Baggerly CA

Legend:

All percentages reference a common baseline of 25 ng/ml as shown on the chart.

%s reflect the disease prevention % at the beginning and ending of available data. Example: Breast cancer incidence is reduced by 30% when the serum level is 34 ng/ml vs the baseline of 25 ng/ml. There is an 83% reduction in incidence when the serum level is 50 ng/ml vs the baseline of 25 ng/ml.

The x's in the bars indicate 'reasonable extrapolations' from the data but are beyond existing data.

References:

All Cancers: Lappe JM, et al. Am J Clin Nutr. 2007;85:1586-91. Breast: Garland CF, Gorham ED, Mohr SB, Grant WB, Garland FC. Breast cancer risk according to serum 25-Hydroxyvitamin D: Meta-analysis of Dose-Response (abstract). American Association for Cancer Research Annual Meeting, 2008. Reference serum 25(OH)D was 5 ng/ml. Garland, CF, et al. Amer Assoc Cancer Research Annual Mtg, April 2008. Colon: Gorham ED, et al. Am J Prev Med. 2007;32:210-6. Diabetes: Hyppönen E, et al. Lancet 2001;358:1500-3. Endometrium: Mohr SB, et al. Prev Med. 2007;45:323-4. Falls: Broe KE, et al. J Am Geriatr Soc. 2007;55:234-9. Fractures: Bischoff-Ferrari HA, et al. JAMA. 2005;293:2257-64. Heart Attack: Giovannucci et al. Arch Intern Med/Vol 168 (No 11) June 9, 2008. Multiple Sclerosis: Munger KL, et al. JAMA. 2006;296:2832-8. Non-Hodgkin's Lymphoma: Purdue MP, et al. Cancer Causes Control. 2007;18:989-99. Ovary: Tworoger SS, et al. Cancer Epidemiol Biomarkers Prev. 2007;16:783-8. Renal: Mohr SB, et al. Int J Cancer. 2006;119:2705-9. Rickets: Arnaud SB, Copyright GrassrootsHealth, 03/23/10 www.grassrootshealth.net